An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 6.63%, which has investors questioning if this is right time to ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

Leading pharmacy benefit managers are shifting away from lucractive rebates on biologic drugs and toward lower-cost ...

A new stroke thrombolytic — tenecteplase — marketed as TNKase — has received FDA approval, marking the first such advancement in nearly 30 years. Unlike alteplase (tPA), which requires a lengthy ...

Researchers used UK Biobank data to identify 70 proteins with genetically predicted roles in asthma, offering insights into ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer ...